SLNO
Soleno Therapeutics Inc

8,215
Mkt Cap
$2.1B
Volume
1.63M
52W High
$90.32
52W Low
$36.67
PE Ratio
-21.26
SLNO Fundamentals
Price
$41.01
Prev Close
$39.16
Open
$39.16
50D MA
$43.69
Beta
0.81
Avg. Volume
1.75M
EPS (Annual)
-$4.38
P/B
4.25
Rev/Employee
$0.00
$1,567.30
Loading...
Loading...

Earnings Recap

• Reported GAAP EPS of $0.82 up 164.57% YoY • Reported revenue of $91.73M • Selling, general and administrative expenses for Soleno Therapeutics are anticipated to increase as the company continues commercialization of VYKAT XR, while also pursuing regulatory approval in other territories, starting with the EU.

Bullish

Soleno Therapeutics achieved strong initial VYKAT XR commercial launch metrics, attained full-year profitability with positive net income, and plans strategic international expansion and pipeline development for DCCR.

Bearish

Soleno Therapeutics faces increasing selling, general, and administrative expenses, significant contingent payment obligations, and inherent product-specific warnings and contraindications for VYKAT XR.

Latest SLNO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.